Contineum Therapeutics, Inc.

CTNM Healthcare Biotechnology

Contineum Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $50.0 million. In the quarter to June 2026, EPS grew 35.5% and free cash flow grew 26.7%, each against the same quarter a year earlier.

7.02 0.88 −11.14%
Market cap
$297.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
37.17 38.00 27.50 29.07
Net Debt/EBITDA
13.68 14.64 15.44 12.28
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.31) (0.44) (0.47) (0.44)
Book value per Share
6.40 6.70 9.42 6.42
Free Cash Flow
(11.51) (16.58) (13.08) (12.29)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates